SAR-444245, an engineered not-alpha IL-2 leveraging synthetic biology, modulates critical components of the immune system for durable anti-tumoral activity
The Journal of Immunology · 2025
DOI: 10.1093/jimmun/vkaf142 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2025. Verfasst von Lina Ma und 16 weiteren Autor:innen. Beteiligte Einrichtung: Synthorx, A Sanofi Company, La Jolla, CA, United States. Hauptthemen laut MEDLINE: Immunotherapy, Interleukin-2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Anti-tumoral immunity requires coordination of diverse responses leading to durable tumor clearance. Immunotherapy leverages specific mechanisms of the immune system to improve effector cell-mediated attack of tumors. We engineered SAR-444245 [SAR’245, formerly known as THOR-707] as a not-alpha interleukin-2 (IL-2) designed for increased half-life and selective targeting of CD8+ T and natural killer (NK) cells while reducing targeting of immune-suppressive CD4+ regulatory T cells (Tregs). The anti-tumoral efficacy of SAR’245 was investigated using the syngeneic CT-26 mouse model characterized by high infiltration with Tregs and responsiveness to programmed cell-death protein-1 (PD-1) checkpoint inhibitory antibodies. We evaluated SAR’245 pharmacokinetics and peripheral and intra-tumoral pharmacodynamics employing cytometry, histochemistry, RNAseq and secreted cytokine readouts, and in vivo efficacy as single-agent and in combination with an anti-mouse PD-1 antibody. In CT-26 tumor-bearing mice, SAR’245 administration induced peripheral expansion of CD8+ T and NK cells, including T cell memory subpopulations, without significant Treg expansion. SAR’245 stimulated anti-tumor activity that was enhanced in combination with an anti-PD-1 checkpoint inhibitory antibody, promoting both long-term survival and rejection of tumor cells on re-challenge. This agent elevated lymphocytic infiltration of tumors and T cell clonal diversity, eliciting multiple intra-tumoral gene signatures reporting on enhanced effector cell activity and persistence in the tumor microenvironment. Overall, we demonstrate that the IL-2 not-alpha agent SAR’245 induces immune responses that promote infiltration of CD8+ T and NK cells with enhanced effector function, leading to durable antitumoral response. These findings suggest SAR’245 potential for the treatment of solid tumors, particularly in combination with inhibitors of PD-1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Synthorx, A Sanofi Company, La Jolla, CA, United States.
Zitieren
APA
Ma, L., Acuff, N. V., Ptacin, J. L., Caffaro, C. E., San Jose, K. M., Aerni, H. R., Herman, R. W., Pavlova, Y., Pena, M. J., Chen, D. B., Pham, H. V., Buetz, C., Esche, E., Koriazova, L. K., Shawver, L. K., Joseph, I. B., & Milla, M. E. (2025). SAR-444245, an engineered not-alpha IL-2 leveraging synthetic biology, modulates critical components of the immune system for durable anti-tumoral activity. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkaf142
Vancouver
Ma L, Acuff NV, Ptacin JL, Caffaro CE, San Jose KM, Aerni HR, et al. SAR-444245, an engineered not-alpha IL-2 leveraging synthetic biology, modulates critical components of the immune system for durable anti-tumoral activity. The Journal of Immunology. 2025. doi:10.1093/jimmun/vkaf142
BibTeX
@article{Ma2025,
author = {Ma, Lina and Acuff, Nicole V and Ptacin, Jerod L and Caffaro, Carolina E and San Jose, Kristine M and Aerni, Hans R and Herman, Rob W and Pavlova, Yelena and Pena, Michael J and Chen, David B and Pham, Helene V and Buetz, Christen and Esche, Ean and Koriazova, Lilia K and Shawver, Laura K and Joseph, Ingrid B and Milla, Marcos E},
title = {SAR-444245, an engineered not-alpha IL-2 leveraging synthetic biology, modulates critical components of the immune system for durable anti-tumoral activity},
journal = {The Journal of Immunology},
year = {2025},
doi = {10.1093/jimmun/vkaf142}
}
EUVIMED